fbpx
End the duopoly

340B found to have minimal effect on pricing, countering notion that it’s a driver of healthcare spending

The 340B drug discount program has been a source of controversy, with the pharmaceutical industry claiming that it’s one of the main drivers of rising healthcare spending. But a study from the Medicare Payment Advisory Commission challenges that assertion, finding that its effect on cost sharing for patients is minimal. For hospitals participating in 340B, spending on cancer drugs was 2 to 5% higher than that of non-participants, and 1 to 7% higher than […]

Related Posts
1 of 1,130

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More